Jove
Visualize
Contact Us

Related Concept Videos

Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The 'sewage unit fish' must further die].

ALTEX·2003
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 10, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

The botulinum neurotoxin LD50 test - problems and solutions.

Silke Bitz

    ALTEX
    |August 6, 2010
    PubMed
    Summary

    The LD50 test for Botulinum Neurotoxin (BoNT) causes animal distress and violates EU cosmetic testing bans. Despite available alternatives, manufacturers and authorities fail to implement them, leading to extensive animal use.

    Area of Science:

    • Toxicology
    • Pharmacology
    • Animal Welfare

    Background:

    • The LD50 test, a standard for Botulinum Neurotoxin (BoNT) potency, is ethically problematic due to severe animal distress.
    • EU regulations ban animal testing for cosmetics, yet BoNT testing persists.
    • The European Pharmacopoeia permits validated alternative methods for BoNT testing.

    Purpose of the Study:

    • To highlight the ethical and regulatory conflicts surrounding the LD50 test for BoNT.
    • To emphasize the non-implementation of validated alternative testing methods.
    • To estimate the global number of animals used in BoNT LD50 tests.

    Main Methods:

    • Review of existing regulations and pharmacopoeia monographs.
    • Analysis of ethical concerns regarding the LD50 test.

    More Related Videos

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
    10:30

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

    Published on: December 27, 2013

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
    14:10

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

    Published on: November 14, 2014

    Related Experiment Videos

    Last Updated: Jun 10, 2026

    Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
    12:25

    Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

    Published on: March 3, 2014

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
    10:30

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

    Published on: December 27, 2013

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
    14:10

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

    Published on: November 14, 2014

  • Estimation of animal usage based on investigative data.
  • Main Results:

    • The LD50 test causes significant animal suffering and contradicts EU cosmetic testing bans.
    • Validated alternative assays for BoNT testing are not utilized by manufacturers.
    • Regulatory authorities have not enforced the adoption of alternative methods or removal of the LD50 test.
    • An estimated 600,000+ mice are used annually worldwide for BoNT LD50 tests.

    Conclusions:

    • The continued use of the LD50 test for BoNT is ethically unjustifiable and legally questionable.
    • There is a critical need for the implementation and enforcement of validated alternative testing methods.
    • Urgent action is required to reduce and ultimately replace animal testing in BoNT potency assays.